Develops antibody and immune-based therapies for infectious diseases and cancer.
Develops antibody and immune-based therapies for infectious diseases and cancer.
Has no approved product on sale, so it is funded by cash built up while its COVID antibody sold, plus occasional partner or grant income. Spending goes on trials, which means results hinge on study readouts rather than sales.
Moat: none (IP / patents). Broad antibody engineering platform but past reliance on a discontinued COVID antibody; no current approved product.
Headquarters: San Francisco, California, US · Founded: 2016 · Employees: 367
Size Vir Biotechnology (VIR) is a United States Health Care company (Biotechnology) with a market value of $1.57B, the 1946th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.15 on 18 Nov 2026.
Performance Over six months the shares gained 3.0%, against -12.8% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 1,696.0% over the last twelve months (peer median +23.4%); the operating margin is -70.2% (peer median 3.4%).
Valuation It trades at 4.0× enterprise value to sales against a peer median of 6.4× (6th cheapest of 18).
Capital Return on invested capital runs 45.0 points below its cost of capital (13.1% WACC).
Short interest Short interest is 9.8% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $303M | $68.6M | $74.2M | $86.2M | $1.62B |
| Revenue growth | — | -8% | -14% | -95% | — |
| Gross profit | $291M | $56.9M | $58.8M | $64.0M | $1.45B |
| EBITDA | -$201M | -$456M | -$509M | -$642M | $849M |
| Net income | -$185M | -$438M | -$522M | -$615M | $516M |
| Free cash flow | -$142M | -$397M | -$454M | -$800M | $1.60B |
| Capital expenditure | $804,000 | $4.83M | $7.30M | $21.6M | $68.0M |
| Total debt | $90.8M | $97.9M | $97.9M | $125M | $128M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vir Biotechnology VIR | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a |
| Gilead Sciences GILD | $210B | +30% | +7% | 38% | 7.3× | -2.4% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 2.8× | -0.1% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.8% | -9.9% | 9th lowest of 21 |
| 6-month return | +3.0% | -12.8% | 6th highest of 20 |
| Distance from 52-week high | -36.4% | -44.5% | 8th highest of 21 |
| Revenue growth (TTM) | +1,696.0% | +23.4% | 2nd highest of 19 |
| Operating margin | -70.2% | 3.4% | 5th lowest of 19 |
| EV / Sales | 4.0× | 6.4× | 6th cheapest of 18 |
| ROIC minus cost of capital | -45.0 pp | -5.9 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |